Template:Androgen replacement therapy formulations and dosages used in women
Jump to navigation
Jump to search
| Route | Medication | Major brand names | Form | Dosage |
|---|---|---|---|---|
| Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
| Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
| Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
| Normethandronea | Ginecoside | Tablet | 5 mg/day | |
| Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
| Prasterone (DHEA)b | – | Tablet | 10–100 mg/day | |
| Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
| Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
| AndroGel | Gel, cream | 1–10 mg/day | ||
| Vaginal | Prasterone (DHEA) | Intrarosa | Insert | 6.5 mg/day |
| Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
| Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
| Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
| Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
| Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
| Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
| Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
| Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks).[1][2] Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: General: [3][4][5][6][7][8][9][10][11][12][13][14][15][16] Specific: [17][18][19][20][21][22][23][24] | ||||
Template documentationSee also
- Template:Androgen/anabolic steroid dosages for breast cancer
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Medications and dosages used in hormone therapy for transgender men
- Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
References
- ↑ P. Mauvais-Jarvis; F. Kuttenn; I. Mowszowicz (6 December 2012). Hirsutism. Springer Science & Business Media. pp. 74–. ISBN 978-3-642-81571-3.
- ↑ Marianne J. Legato (29 October 2009). Principles of Gender-Specific Medicine. Academic Press. pp. 748–. ISBN 978-0-08-092150-1.
- ↑ Lobo, Rogerio A. (2001). "Androgens in Postmenopausal Women: Production, Possible Role, and Replacement Options". Obstetric and Gynecologic Survey. 56 (6): 361–376. doi:10.1097/00006254-200106000-00022. ISSN 0029-7828.
- ↑ Morley JE, Perry HM (May 2003). "Androgens and women at the menopause and beyond". J. Gerontol. A Biol. Sci. Med. Sci. 58 (5): M409–16. doi:10.1093/gerona/58.5.M409. PMID 12730248.
- ↑ Rogerio A. Lobo; Jennifer Kelsey; Robert Marcus (22 May 2000). Menopause: Biology and Pathobiology. Academic Press. pp. 454–. ISBN 978-0-08-053620-0.
- ↑ Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 374–. ISBN 978-1-59259-388-0.
- ↑ Jacques Lorrain (1994). Comprehensive Management of Menopause. Springer Science & Business Media. pp. 301–. ISBN 978-0-387-97972-4.
- ↑ Khorram O (December 2001). "Potential therapeutic effects of prescribed and over-the-counter androgens in women". Clin Obstet Gynecol. 44 (4): 880–92. doi:10.1097/00003081-200112000-00025. PMID 11600868.
- ↑ Barbara G. Wells; Joseph T. DiPiro; Terry L. Schwinghammer; Cecily V. DiPiro (22 August 2014). Pharmacotherapy Handbook, 9/E. McGraw-Hill Education. p. 288. ISBN 978-0-07-182129-2.
- ↑ David B. Seifer (27 July 1999). Menopause: Endocrinology and Management. Springer Science & Business Media. pp. 359–. ISBN 978-1-59259-246-3.
- ↑ Alexandre Hohl (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 341–343. ISBN 978-3-319-46086-4.
- ↑ Margaret Nusbaum; Jo Ann Rosenfeld (2 December 2004). Sexual Health Across the Lifecycle: A Practical Guide for Clinicians. Cambridge University Press. pp. 77–. ISBN 978-0-521-53421-5.
- ↑ Davis SR (1999). "The therapeutic use of androgens in women". J. Steroid Biochem. Mol. Biol. 69 (1–6): 177–84. doi:10.1016/S0960-0760(99)00054-0. PMID 10418991.
- ↑ Maia H, Casoy J, Valente J (January 2009). "Testosterone replacement therapy in the climacteric: benefits beyond sexuality". Gynecol. Endocrinol. 25 (1): 12–20. doi:10.1080/09513590802360744. PMID 19165658.
- ↑ Greenblatt, K. B. (2009). "Is there a place for androgens in gynecological disorders?". Gynecological Endocrinology. 1 (2): 209–219. doi:10.3109/09513598709030684. ISSN 0951-3590.
- ↑ Shabsigh, Ridwan; Davis, Anne R.; Anastasiadis, Aristotelis G.; Makhsida, Nawras; Yan, Grace (2005). "Female Sexual Dysfunction": 423–443. doi:10.1385/1-59259-871-4:423.
{{cite journal}}: Cite journal requires|journal=(help) - ↑ Marek Josef; a kolektiv (14 May 2010). Farmakoterapie vnitřních nemocí: 4., zcela přepracované a doplněné vydání. Grada Publishing a.s. pp. 380–. ISBN 978-80-247-9524-9.
In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.
- ↑ Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197.
Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.
- ↑ Laura Marie Borgelt (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 558–. ISBN 978-1-58528-194-7.
Despite the lack of clinical trials and quality-control standards, custom-compounded testosterone creams, ointments, and gel forms are popular formulations for improving women's sexual desire.68-70 For women, an appropriate dosage of compounded 1% testosterone gel, cream, or ointment is 0.5 g/day, which should deliver 5 mg of testosterone daily, one tenth the generally prescribed dosage for men.39 The product can be applied directly to any skin surface (but commonly the clitoris, labia, thigh, arm, or abdomen) several times weekly.
- ↑ Patrick J. Culligan; Roger P. Goldberg (6 March 2007). Urogynecology in Primary Care. Springer Science & Business Media. pp. 116–. ISBN 978-1-84628-167-9.
Topical vaginal testosterone is often used in premenopausal women as a first step in the treatment of sexual dysfunction and vaginal lichen planus. Topical testosteorne preparations can be compounded in 1% to 2% formulations and should be applied up to 3 times per week.
- ↑ Maxine A. Papadakis; Stephen J. McPhee; Michael W. Rabow (11 September 2017). Current Medical Diagnosis and Treatment 2018, 57th Edition. McGraw-Hill Education. p. 1217–1218. ISBN 978-1-259-86149-9.
Testosterone can also be compounded as a cream containing 1 mg/mL, with 1 mL applied to the abdomen daily. Vaginal testosterone is an option for postmenopausal women who cannot use systemic or vaginal estrogen due to breast cancer. Testosterone 150–300 mcg/day vaginally appears to reduce vaginal dryness and dyspareunia without increasing systemic estrogen levels.
- ↑ Joseph E. Pizzorno (2013). Textbook of Natural Medicine. Elsevier Health Sciences. pp. 1602–. ISBN 1-4377-2333-0.
At present, bioidentical testosterone can be obtained only from a compounding pharmacy, where 4 to 6 mg of bioidentical testosterone is generally formulated alone or together with the biestrogen or triestrogen formulation. Testosterone cream applied to the genital region can be used as an alternative delivery method. Common prescriptions are anywhere from 1 to 10 mg/g of cream.
- ↑ "Intrarosa Information Sheet" (PDF). FDA.gov. Retrieved January 4, 2019.
- ↑ Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. pp. 18–19, 336. ISBN 978-0-12-137250-7.